Evidence map›Paper›PMID 41585782›Full record

ArticleThe Pan African medical journal2025

Mpox in endemic regions in Nigeria: awareness, knowledge, and willingness to accept the mpox vaccine.

Isaac Iyinoluwa Olufadewa, Miracle Ayomikun Adesina, Ruth Ifeoluwa Oladele, Toluwase Ayobola Olufadewa, Evaezi Okpokoro, Oluwafemi Babatunde Daodu, Fehintola Ige, Sylvia Adebajo, Ehimario Uche Igumbor, Moyinoluwa Joshua Oladoye and 3 more

Abstract read
In one paragraph

Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Isaac Iyinoluwa OlufadewaCentre for One Health and Zoonotic Diseases, Slum and Rural Health Initiative, Ibadan, Nigeria.
Miracle Ayomikun AdesinaCentre for One Health and Zoonotic Diseases, Slum and Rural Health Initiative, Ibadan, Nigeria.
Ruth Ifeoluwa OladeleCentre for One Health and Zoonotic Diseases, Slum and Rural Health Initiative, Ibadan, Nigeria.
Toluwase Ayobola OlufadewaCentre for One Health and Zoonotic Diseases, Slum and Rural Health Initiative, Ibadan, Nigeria.
Evaezi OkpokoroInternational Research Centre of Excellence, Institute of Human Virology, Nigeria, Abuja, Nigeria.
Oluwafemi Babatunde DaoduDepartment of Veterinary Microbiology, Virology Unit, Faculty of Veterinary Medicine, University of Ilorin, Ilorin, Kwara State, Nigeria.
Fehintola IgeCentre for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Sylvia AdebajoInternational Research Centre of Excellence, Institute of Human Virology, Nigeria, Abuja, Nigeria.
Ehimario Uche IgumborCentre for Infectious Diseases Research, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Moyinoluwa Joshua OladoyeCentre for One Health and Zoonotic Diseases, Slum and Rural Health Initiative, Ibadan, Nigeria.
Joseph Ojonugwa ShaibuCentre for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Dimie OgoinaDepartment of Internal Medicine, Infectious Diseases Unit, Niger Delta University Teaching Hospital, Bayelsa, Nigeria.
Rosemary Ajuma AuduCentre for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Nigeria ranks second in Africa for the highest number of mpox cases. This study aimed to evaluate the knowledge and awareness of mpox among Nigerians living in endemic regions and their willingness to accept the mpox vaccine when available. Methods: we conducted a cross-sectional study using a multi-stage sampling technique. Data was collected from eligible individuals in Bayelsa, Delta, Lagos, and Rivers, Nigeria, between September 1 and November 30, 2023, using a standardized structured questionnaire. Descriptive analysis was conducted, and inferential analyses were performed using binary logistic regression (p < 0.05). Results: five hundred and twenty-four (524) persons with a mean age of 33.9 ± 10.4 years participated in this study. Fifty-eight percent (58%) were aware of mpox, and 15.5% of participants had heard about the mpox vaccine. Participants from Delta State were 70 percent less likely, while those from Lagos and Rivers States were 2.5 times and 1.04 times, respectively (OR= 2.48, p=0.012; OR= 1.04, p=0.89) more likely to receive the mpox vaccine when compared with participants from Bayelsa State. Eighty-four (84.5%) of respondents were unwilling to take the vaccine if they had to pay for it. Conclusion: although many people were aware of the mpox infection, only a few people were aware of the vaccine. Health intervention programs to improve knowledge of mpox and increase the uptake of mpox vaccines should be co-designed with community stakeholders, while mpox vaccines, when available, should be made accessible at subsidized or at no cost to Nigerians to improve uptake.

Indexed as

Health Knowledge, Attitudes, PracticeMpox, MonkeypoxPatient Acceptance of Health CareSmallpox VaccineVaccinationAdolescentAdultCross-Sectional StudiesEndemic DiseasesFemaleHumansMaleMiddle AgedNigeriaSurveys and QuestionnairesYoung AdultSmallpox VaccineawarenessendemicKnowledgempox vaccinempox virusNigeria

Identifiers

PMID41585782
PMCPMC12831209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.